Free Trial

Faron Pharmaceuticals Oy (FARN) Competitors

Faron Pharmaceuticals Oy logo
GBX 28.10 -0.20 (-0.71%)
As of 07:10 AM Eastern

FARN vs. AVCT, ARIX, CIR, TILS, and VSN

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? Faron Pharmaceuticals Oy's main competitors and comparable companies include Avacta Group (AVCT), Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to Avacta Group?

Faron Pharmaceuticals Oy (LON:FARN) and Avacta Group (LON:AVCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, Faron Pharmaceuticals Oy and Faron Pharmaceuticals Oy both had 1 articles in the media. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Faron Pharmaceuticals Oy
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avacta Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Avacta Group's net margin of -35,730.97%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 476.49% -70.00%
Avacta Group -35,730.97%-1,293.07%-21.80%

Avacta Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Avacta Group is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A
Avacta Group£113K2,218.30-£30.08M-£9.24N/A

3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 2.9% of Avacta Group shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 49.1% of Avacta Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Faron Pharmaceuticals Oy has a beta of 1.116, meaning that its share price is 12% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Summary

Avacta Group beats Faron Pharmaceuticals Oy on 6 of the 10 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arix Bioscience£14.16M0.00£14.96M£0.11N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

41.3% of Arix Bioscience shares are owned by institutional investors. Comparatively, 3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 20.7% of Arix Bioscience shares are owned by insiders. Comparatively, 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Arix Bioscience. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Arix Bioscience. Arix Bioscience's average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score.

Company Overall Sentiment
Arix Bioscience Neutral
Faron Pharmaceuticals Oy Neutral

Arix Bioscience has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.116, suggesting that its stock price is 12% more volatile than the broader market.

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat Arix Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Arix Bioscience105.64% 6.41% 2.18%
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 11 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Faron Pharmaceuticals Oy (LON:FARN) and Circassia Group (LON:CIR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Circassia Group. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Circassia Group Neutral

Circassia Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A
Circassia Group£27.90M0.00N/A£0.01N/A

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Circassia Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 476.49% -70.00%
Circassia Group N/A N/A N/A

3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Faron Pharmaceuticals Oy and Circassia Group tied by winning 4 of the 8 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Tiziana Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Faron Pharmaceuticals Oy N/A 476.49%-70.00%

Tiziana Life Sciences has higher earnings, but lower revenue than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for Faron Pharmaceuticals Oy. Tiziana Life Sciences' average media sentiment score of 0.25 beat Faron Pharmaceuticals Oy's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tiziana Life Sciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Faron Pharmaceuticals Oy
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Faron Pharmaceuticals Oy beats Tiziana Life Sciences on 6 of the 9 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verseon?

Faron Pharmaceuticals Oy (LON:FARN) and Verseon (LON:VSN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Verseon's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 476.49% -70.00%
Verseon N/A N/A N/A

3.2% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Faron Pharmaceuticals Oy and 0 mentions for Verseon. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Verseon Neutral

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A
VerseonN/AN/AN/A-£14.30N/A

Summary

Faron Pharmaceuticals Oy beats Verseon on 6 of the 7 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FARN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FARN vs. The Competition

MetricFaron Pharmaceuticals OyBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£57.01M£4.11B£7.88B£2.84B
Dividend YieldN/A3.64%2.47%5.11%
P/E Ratio-2.4424.5133.3323.37
Price / SalesN/A15.118.125.05
Price / Cash20.0021.8921.0220.23
Price / Book0.014.414.802.51
Net Income-£60.23M-£24.19M£3.52B£5.88B
7 Day Performance-5.80%-6.16%-4.56%-0.01%
1 Month Performance-17.96%-3.80%-2.78%-2.15%
1 Year Performance-84.81%-3.50%0.12%7.21%

Faron Pharmaceuticals Oy Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FARN
Faron Pharmaceuticals Oy
N/AGBX 28.10
-0.7%
N/A-84.7%£57.01MN/AN/A34
AVCT
Avacta Group
N/AGBX 53.80
-3.9%
N/A-26.1%£235.45M£113KN/A120
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11

Related Companies and Tools


This page (LON:FARN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners